Articles About generic competition

  • Teva Pharmaceutical Inudstries Ltd. (NYSE:TEVA) has had a bit of a rough year so far: the first quarter of 2014 seems to have been primarily taken up by Teva’s attempts at winning an ongoing battle to delay generic versions of the company’s top-selling multiple sclerosis drug, Copaxone, a drug which was responsible for more than half the Read More »


Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business